

Edgar Filing: INCARA PHARMACEUTICALS CORP - Form 10-Q/A

INCARA PHARMACEUTICALS CORP
Form 10-Q/A
July 31, 2001

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q/A

Amendment No. 1

X Quarterly report pursuant to Section 13 or 15(d) of the Securities
----- Exchange Act of 1934 for the quarterly period ended March 31, 2001.

----- Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 for the transition period from _____ to _____.

Commission File Number
0-27410

INCARA PHARMACEUTICALS CORPORATION

(Exact Name of Registrant as Specified in its Charter)

Delaware

56-1924222

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identificat

P.O. Box 14287
79 T.W. Alexander Drive
4401 Research Commons, Suite 200
Research Triangle Park, NC

27709

(Address of Principal Executive Office)

(Zip Code)

Registrant's Telephone Number, Including Area Code

919-558-8688

3200 East Highway 54, Cape Fear Building, Suite 200
Research Triangle Park, North Carolina 27709

(Former address of Principal Executive Office)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. YES X NO

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.

Class	Outstanding as of July 25, 2001
-----	-----
Common Stock, par value \$.001	8,380,320 Shares

Edgar Filing: INCARA PHARMACEUTICALS CORP - Form 10-Q/A

INCARA PHARMACEUTICALS CORPORATION

INDEX TO FORM 10-Q

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Consolidated Balance Sheets as of March 31, 2001 (unaudited)
and September 30, 2000.....

Consolidated Statements of Operations for the Three Months and Six
Months ended March 31, 2001 and 2000 (unaudited).....

Consolidated Statements of Cash Flows for the Six Months ended
March 31, 2001 and 2000 (unaudited).....

Notes to Consolidated Financial Statements.....

Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations.....

PART II. OTHER INFORMATION

Item 2. Changes in Securities.....

Item 4. Submission of Matters to a Vote of Security Holders.....

Item 6. Exhibits and Reports on Form 8-K.....

SIGNATURE.....

Explanatory Note

This Amendment No. 1 on Form 10-Q/A is being filed in order to amend and
restate the financial statements filed as part of our Form 10-Q filed on May 14,
2001, as described herein.

INCARA PHARMACEUTICALS CORPORATION

CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except per share data)

March 31,
2001

(Unaudited)

ASSETS

Edgar Filing: INCARA PHARMACEUTICALS CORP - Form 10-Q/A

Current assets:	
Cash and cash equivalents	\$ 4,954
Marketable securities	-
Accounts receivable from Incara Development	385
Other accounts receivable	-
Prepays and other current assets	582

Total current assets	5,921

Property and equipment, net	338
Other assets	356

	\$ 6,615
	=====
LIABILITIES AND STOCKHOLDERS' EQUITY	
Current liabilities:	
Accounts payable	\$ 843
Accrued expenses	218
Accumulated losses of Incara Development in excess of investment	308
Current portion of capital lease obligations	23
Current portion of note payable	-

Total current liabilities	1,392
Long-term portion of capital lease obligations	31
Stockholders' equity:	
Preferred stock, \$.01 par value per share, 3,000,000 shares authorized	
Series C convertible exchangeable preferred stock, 20,000 shares authorized; 12,015 and no shares issued and outstanding as of March 31, 2001 and September 30, 2000, respectively (liquidation value of \$18,031)	1
Series B convertible preferred stock, 600,000 shares authorized; 28,457 and no shares issued and outstanding as of March 31, 2001 and September 30, 2000, respectively	1
Common stock, \$.001 par value per share, 40,000,000 shares authorized; 8,385,171 and 7,365,849 shares issued and outstanding at March 31, 2001 and September 30, 2000, respectively	8
Additional paid-in capital	99,046
Restricted stock	(179)
Accumulated deficit	(93,685)

Total stockholders' equity	5,192

	\$ 6,615
	=====

The accompanying notes are an integral part of these consolidated financial statements.

Edgar Filing: INCARA PHARMACEUTICALS CORP - Form 10-Q/A

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data)

	Three Months Ended March 31,		
	2001	2000	
Revenue:			
Cell processing revenue	\$ 3	\$ -	\$
Contract revenue	-	-	
Total revenue	3	-	
Costs and expenses:	1,568	1,246	
Research and development			
Purchase of in-process research and development	-	6,664	
General and administrative	763	690	
Total costs and expenses	2,331	8,600	
Loss from operations	(2,328)	(8,600)	
Gain on sale of division	-	-	
Gain on settlement of accrued liability	-	-	
Equity in loss of Incara Development	(5,669)	-	
Investment income, net	72	140	
Net loss	(7,925)	(8,460)	
Preferred stock dividend accreted	(214)	-	
Net loss attributable to common stockholders	\$ (8,139)	\$ (8,460)	\$
Net loss per weighted share attributable to common stockholders:			
Basic and diluted	\$ (1.05)	\$ (1.80)	\$
Weighted average common shares outstanding	7,754	4,712	

The accompanying notes are an integral part of these consolidated financial statements.

Edgar Filing: INCARA PHARMACEUTICALS CORP - Form 10-Q/A

	Six Month March
	----- 2001 -----
Cash flows from operating activities:	
Net loss	\$ (9,564)
Adjustments to reconcile net loss available to common stockholders to net cash used in operating activities:	
Depreciation and amortization	55
Noncash compensation	63
Purchase of in-process research and development	-
Gain on sale of division	-
Equity in loss of Incara Development	5,804
Loss on disposal of property and equipment	-
Gain on settlement of accrued liability	(767)
Change in assets and liabilities:	
Accounts receivable	(382)
Prepays and other current assets	(179)
Other assets	(356)
Accounts payable and accrued expenses	(89)
Net cash used in operating activities	----- (5,415) -----
Cash flows from investing activities:	
Proceeds from sale of division	-
Proceeds from sales of marketable securities	4,678
Purchases of property and equipment	(200)
Net cash provided by investing activities	----- 4,478 -----
Cash flows from financing activities:	
Proceeds from issuance of common stock	2,638
Proceeds from issuance of Series B preferred stock and warrants	1,414
Repurchase of Incara common stock	-
Principal payments on notes payable	(27)
Principal payments on capital lease obligations	(11)
Net cash provided by (used in) financing activities	----- 4,014 -----
Net increase in cash and cash equivalents	3,077
Cash and cash equivalents at beginning of period	1,877
Cash and cash equivalents at end of period	\$ 4,954 =====
Supplemental disclosure of financing activities:	
Common stock issued in settlement of accrued liability	\$ 416 =====
Retirement of common stock in connection with settlement of accrued liability	\$ 83 =====
Series C preferred stock issued for investment in Incara Development	\$ 5,496 =====

The accompanying notes are an integral part of these unaudited consolidated financial statements.

5

INCARA PHARMACEUTICALS CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

A. Basis of Presentation

The "Company" refers collectively to Incara Pharmaceuticals Corporation, a Delaware corporation ("Incara"), its wholly owned subsidiaries, Aeolus Pharmaceuticals, Inc., a Delaware corporation, and Incara Cell Technologies, Inc., a Delaware corporation, formerly Renaissance Cell Technologies, Inc., and its equity investee, Incara Development, Ltd., a Bermuda corporation ("Incara Development"). As of March 31, 2001, Incara owned 80.1% of Incara Development.

Incara is developing therapies focused on tissue protection, repair and regeneration. In particular, the Company is focused on developing adult stem cell therapy for the treatment of liver failure. The Company is also conducting research and development of a series of catalytic antioxidant molecules and, in collaboration with Elan Corporation, plc, is conducting a Phase 2/3 clinical trial of an ultra low molecular weight heparin for the treatment of ulcerative colitis.

All significant intercompany activity has been eliminated in the preparation of the consolidated financial statements. The unaudited consolidated financial statements have been prepared in accordance with the requirements of Form 10-Q and Rule 10-01 of Regulation S-X. Some information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations. In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the consolidated financial position, results of operations and cash flows of the Company. The consolidated balance sheet at September 30, 2000 was derived from the Company's audited financial statements included in the Company's Annual Report on Form 10-K. The unaudited consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2000 and in the Company's other Securities and Exchange Commission ("SEC") filings. Results for the interim period are not necessarily indicative of the results for any other interim period or for the full fiscal year.

B. Recent Accounting Pronouncements

The Company adopted Statement of Financial Accounting Standards No. 133, as amended, "Accounting for Derivative Instruments and Hedging Activities" ("SFAS 133"), in October 2000. SFAS 133 establishes accounting and reporting standards for derivative instruments, including certain derivative instruments embedded in other contracts (collectively referred to as derivatives), and for

Edgar Filing: INCARA PHARMACEUTICALS CORP - Form 10-Q/A

hedging activities. The Company does not currently use nor does it intend in the future to use derivative instruments, and, therefore, the adoption of SFAS 133 did not have any impact on the Company's financial position or results of operations.

6

C. Net Loss Per Weighted Share Attributable to Common Stockholders

The Company computes basic net loss per weighted share attributable to common stockholders using the weighted average number of shares of common stock outstanding during the period. Diluted net loss per weighted share attributable to common stockholders is computed using the weighted average number of shares of common and dilutive potential common shares outstanding during the period. Potential common shares consist of stock options, restricted common stock, warrants and convertible preferred stock using the treasury stock method and are excluded if their effect is antidilutive. As of March 31, 2001, diluted weighted average common shares excludes incremental shares of approximately 4,854,000 related to stock options, restricted common stock, convertible preferred stock, and warrants to purchase common and preferred stock. These shares are excluded due to their antidilutive effect as a result of the Company's loss from operations during the three and six months ended March 31, 2001.

D. Commitments and Contingencies

In December 1999, Incara sold IRL, its anti-infectives division, to a private pharmaceutical company. Incara remains contingently liable through May 2007 on remaining debt and lease obligations of approximately \$7,400,000 assumed by the purchaser, including the IRL facility lease in Cranbury, New Jersey.

In January 2001, Incara entered into a five-year non-cancelable operating lease for additional office and laboratory facilities, with future minimum payments under the new lease totaling \$1,926,000.

E. Knoll Settlement

On December 20, 2000, Incara entered into a Settlement Agreement and Release with Knoll AG ("Knoll") to resolve a dispute regarding a payable owed by Incara to Knoll for a discontinued program. As of the settlement date, the accrued liability, net of related receivables, was \$1,250,000. Incara paid Knoll \$70,000 and issued to Knoll 175,000 shares of common stock (with a fair value of approximately \$416,000) in exchange for a full release of all amounts owed to Knoll. This settlement eliminated the accrued liability owed to Knoll and reduced Incara's net loss by \$767,000 in the first quarter of fiscal 2001.

F. Elan Transaction

On January 22, 2001, Incara closed on a collaborative transaction with Elan Corporation, plc, an Irish company ("Elan"), Elan International Services, Ltd., a Bermuda company ("Elan International"), and Elan Pharma International Limited, an Irish company ("Elan Pharma"). As part of the transaction, Elan International and Incara formed a Bermuda corporation, Incara Development, Ltd., to develop OP2000. Incara owns all of the common stock and 60.2% of the non-voting preferred shares of Incara Development and Elan International owns 39.8% of the non-voting preferred shares of Incara Development. Of the outstanding combined common and non-voting preferred shares of Incara Development, Incara owns 80.1% and Elan International owns 19.9%. As part of the

Edgar Filing: INCARA PHARMACEUTICALS CORP - Form 10-Q/A

transaction, Elan, Elan Pharma and Incara entered into license

7

agreements under which Incara licensed to Incara Development the OP2000 compound and Elan Pharma licensed to Incara Development proprietary drug delivery technology.

As part of the transaction, Elan International also purchased 825,000 shares of Incara's common stock, 28,457 shares of Incara Series B non-voting convertible preferred stock ("Series B Stock") and a five-year warrant to purchase 22,191 shares of Series B Stock at an exercise price of \$72.12 per share for an aggregate purchase price of \$4,000,000. Each share of Series B Stock is convertible into ten shares of common stock. Elan International also purchased shares of Incara Series C convertible exchangeable non-voting preferred stock ("Series C Stock"). The Series C Stock has a face value of \$12,015,000 and bears a mandatory stock dividend of 7%, compounded annually. The Series C Stock is exchangeable at the option of Elan International at any time for all of the preferred stock of Incara Development held by Incara which, if exchanged, would give Elan International ownership of 50% of the initial amount of combined common and preferred stock of Incara Development. After December 20, 2002, the Series C Stock is convertible by Elan International into shares of Incara's Series B Stock at the rate of \$64.90 per share. If the Series C Stock is outstanding as of December 21, 2006, Incara will exchange the Series C Stock and accrued dividends, at its option, for either cash or shares of stock and warrants of Incara having a then fair market value of the amount due. The proceeds from the issuance of the Series C Stock were contributed by Incara to Incara Development. Consequently, the value initially recorded as Incara's investment in Incara Development is the same as the fair value of the Series C Stock issued, which was approximately \$5,496,000. This value is the estimated fair market value of Incara's common stock into which the Series C Stock could have converted, calculated as of the closing date. The technology obtained by Incara Development from Elan and Elan Pharma was expensed at inception because the feasibility of using the contributed technology in conjunction with OP2000 had not been established and Incara Development had no alternative future use for the contributed technology. Incara immediately expensed as equity in loss of Incara Development its investment in Incara Development, reflective of Incara's pro rata interest in Incara Development. From the date of issue up to December 21, 2006, Incara will accrete the Series C Stock from its recorded value up to its face value plus the 7% dividend.

Upon the later of the completion of enrollment of a Phase 2/3 clinical trial for OP2000 or December 21, 2001, Elan International will purchase \$1,000,000 of Incara's Series B Stock at a per share price that will be ten times the greater of (a) the average per share price of Incara common stock for the day prior to the purchase, or (b) a 25% premium to the average daily price per share of Incara common stock for the 60 trading day period immediately prior to the purchase. In addition, as part of the \$1,000,000 payment, Incara will issue to Elan International a five-year warrant for 20% of the shares of Series B Stock purchased by Elan International. The exercise price of the Series B Stock under this warrant will be equal to twice the per share purchase price of the Series B Stock purchased on the same date.

Elan International and Incara intend to fund Incara Development pro rata, based on their respective percentage ownership of the combined outstanding common and preferred stock of Incara Development. Subject to mutual agreement, Elan Pharma will lend Incara up to \$4,806,000 to fund Incara's pro rata share of development funding for Incara Development. In return, Incara issued a convertible promissory note that bears interest at 10% compounded semi-

8

Edgar Filing: INCARA PHARMACEUTICALS CORP - Form 10-Q/A

annually on the amount outstanding thereunder. After December 20, 2002, the note is convertible at the option of Elan Pharma into shares of Series B Stock at \$43.27 per share. The note will mature on December 21, 2006, when the outstanding principal plus accrued interest will be due and payable. Incara has the option to repay the note either in cash or in shares of Series B Stock and warrants having a then fair market value of the amount due. As of March 31, 2001, Incara had not borrowed any funds pursuant to this note.

While Incara owns 80.1% of the outstanding stock of Incara Development, Elan and its subsidiaries have retained significant minority investor rights that are considered "participating rights" as defined in the Emerging Issues Task Force Consensus No. 96-16. Accordingly, Incara does not consolidate the financial statements of Incara Development, but instead accounts for its investment in Incara Development under the equity method of accounting. Net losses of Incara Development will be recognized by Incara at its 80.1% interest to the extent of Incara's investments, advances and commitments to make future investments in or advances to Incara Development. Further, because Elan can exchange its investment in Incara's Series C Stock for Incara's 30.1% preferred interest in Incara Development, Incara will only recognize 50% of any accumulated net earnings of Incara Development. During the three months and six months ended March 31, 2001, Incara's equity in loss of Incara Development was \$5,669,000, which included \$5,496,000 for Incara's interest in the immediate write-off at inception of the contributed technology by Elan and Elan Pharma to Incara Development and \$173,000 for net losses.

G. REVISION OF EARNINGS PER SHARE

In July 2001, the Company determined its earnings per share calculation required revision as the Company had included certain restricted common shares in the earnings per share calculation, which shares should only be considered in calculating diluted earnings per share during periods in which the Company had income. As a result, the basic and diluted loss per share for the three months ended March 31, 2001 and 2000 as reported was \$1.00 and \$1.53, respectively, and as revised was \$1.05 and \$1.80, respectively. For the six months ended March 31, 2001 and 2000, the basic and diluted loss per share as reported was \$1.26 and \$0.29, respectively, and as revised was \$1.33 and \$0.35, respectively. For the quarter ended December 31, 2000, the basic and diluted loss per share as reported was \$0.21 and as revised was \$0.24. For the comparative quarter ended December 31, 1999, the basic and diluted income per share as reported was \$1.33 and \$1.26, respectively, and as revised was \$1.72 and \$1.39, respectively.

9

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Introduction

Unless otherwise noted, the phrase "we" or "our" refers collectively to Incara Pharmaceuticals Corporation and our wholly owned subsidiaries, Aeolus Pharmaceuticals, Inc. and Incara Cell Technologies, Inc., formerly Renaissance Cell Technologies, Inc., and our equity investee Incara Development. As of March 31, 2001, Incara owned 80.1% of Incara Development.

This Report contains, in addition to historical information, statements by us with respect to expectations about our business and future results, which are "forward-looking" statements under the Private Securities Litigation Reform Act of 1995. These statements and other statements made elsewhere by us or our

Edgar Filing: INCARA PHARMACEUTICALS CORP - Form 10-Q/A

representatives, which are identified or qualified by words such as "likely," "will," "suggests," "expects," "might," "believe," "could," "should," "may," "estimates," "potential," "predict," "continue," "would," "anticipates" or "plans," or similar expressions, are based on a number of assumptions that are subject to risks and uncertainties. Actual results could differ materially from those currently anticipated or suggested due to a number of factors, including those set forth herein, those set forth in our Annual Report on Form 10-K and in our other SEC filings, and including risks relating to the early stage of products under development, uncertainties relating to clinical trials and regulatory reviews, the need for additional funds, competition and dependence on collaborative partners. All forward-looking statements are based on information available as of the date hereof, and we do not assume any obligation to update forward-looking statements.

We are developing therapies focused on tissue protection, repair and regeneration. In particular, we are focused on developing adult stem cell therapy for the treatment of liver failure. We are also conducting research and development of a series of catalytic antioxidant molecules that we believe will have important application in our liver stem cell program as well as in other areas of cell therapy. Outside our main internal focus, our catalytic antioxidant program provides strategic opportunities for collaboration with larger pharmaceutical companies in areas such as stroke and the prevention of side effects induced by radiation in cancer therapy. We are actively pursuing such collaborations. We are also, in collaboration with Elan Corporation, plc, conducting a Phase 2/3 trial of an ultra low molecularweight heparin for the treatment of ulcerative colitis.

On December 29, 1999, we sold our anti-infectives division, known as Incara Research Laboratories, or IRL, to a private pharmaceutical company for \$11,000,000. The transaction involved the sale of assets associated with Incara's anti-infectives division and the assumption by the purchaser of certain related liabilities. We remain contingently liable through May 2007 on remaining debt and lease obligations of approximately \$7,400,000 assumed by the purchaser, including the IRL facility lease in Cranbury, New Jersey. We recognized a gain of \$9,751,000 on the sale of IRL in the first quarter of fiscal 2000.

10

Results of Operations

We incurred net losses attributable to common stockholders of \$8,139,000 and \$9,778,000 for the three and six months ended March 31, 2001, respectively. The net losses attributable to common stockholders for the three and six months ended March 31, 2000 were \$8,460,000 and \$1,537,000, respectively. The net loss for the six months ended March 31, 2001 was reduced by a \$767,000 gain recognized on the settlement of a disputed accrued liability for a discontinued program and the net loss for the six months ended March 31, 2000 was reduced by the \$9,751,000 gain on the sale of IRL.

The net loss for the three and six months ended March 31, 2001 also includes equity losses in Incara Development of \$5,669,000 related to operating losses for Incara Development's initial quarter and the immediate write-off of the contributed technology.

We had cell processing revenue of \$3,000 for the three months and six months ended March 31, 2001. This revenue resulted from fees we earned for processing liver cells that are used for research purposes by other companies. Contract revenue of \$100,000 for the six months ended March 31, 2000 resulted from a collaboration that we sold with our IRL division in December 1999.

Edgar Filing: INCARA PHARMACEUTICALS CORP - Form 10-Q/A

Our research and development, or R&D, expenses increased \$322,000, or 26%, to \$1,568,000 for the three months ended March 31, 2001 from \$1,246,000 for the three months ended March 31, 2000. R&D expenses decreased \$250,000, or 7%, to \$3,375,000 for the six months ended March 31, 2001 from \$3,625,000 for the six months ended March 31, 2000. R&D expenses for the six months ended March 31, 2000 included \$1,376,000 of expenses for IRL, which was sold in December 1999.

R&D expenses for our liver cell program increased \$237,000, or 87%, to \$510,000 for the three months ended March 31, 2001 from \$273,000 for the three months ended March 31, 2000. These R&D expenses increased \$511,000, or 104%, to \$1,004,000 for the six months ended March 31, 2001 from \$493,000 for the six months ended March 31, 2000. Expenses were higher this quarter and fiscal year due to increased activity in the program, including increases in consultants, sponsored research, headcount and patent fees.

R&D expenses for our antioxidant program increased \$361,000, or 117%, to \$670,000 for the three months ended March 31, 2001 from \$309,000 for the three months ended March 31, 2000. These R&D expenses increased \$740,000, or 129%, to \$1,314,000 for the six months ended March 31, 2001 from \$574,000 for the six months ended March 31, 2000. In February 2001, we announced the selection of a catalytic antioxidant compound for late-stage preclinical development to support an Investigational New Drug, or IND, application for the treatment of ischemic stroke. R&D expenses were higher this quarter and fiscal year due to increased activity in the program, including the costs of process improvement and scale-up of the IND compound.

In January 2001, Incara contributed its OP2000 compound being developed for inflammatory bowel disease to Incara Development. R&D expenses incurred prior to January 2001 were on behalf of Incara while R&D expenses incurred after December 2000 were on

11

behalf of Incara Development. Expenses for OP2000 of \$461,000 and \$733,000 for the three months and six months ended March 31, 2000, respectively, were included in R&D expenses during fiscal 2000. Concurrent with Incara's investment in Incara Development, R&D work by Incara for OP2000 is performed on behalf of Incara Development. Amounts billable to Incara Development for OP2000 for expenses incurred and work performed by Incara are netted against R&D expenses. Subsequent to our investment in Incara Development, our expenses associated with OP2000 development are shown as "Equity in loss of Incara Development." While Incara owns 80.1% of the outstanding stock of Incara Development, Elan and its subsidiaries have retained significant minority investor rights that are considered "participating rights" as defined in the Emerging Issues Task Force Consensus No. 96-16. Accordingly, Incara does not consolidate the financial statements of Incara Development, but instead accounts for its investment in Incara Development under the equity method of accounting. Net losses of Incara Development will be recognized by Incara at its 80.1% interest to the extent of Incara's investments, advances and commitments to make future investments in or advances to Incara Development. Further, since Elan can exchange its investment in Incara's Series C Stock for Incara's 30.1% preferred interest in Incara Development, Incara will only recognize 50% of any accumulated net earnings of Incara Development. During the three months and six months ended March 31, 2001, our equity in loss of Incara Development was \$5,669,000, which included \$5,496,000 for Incara's interest in the immediate write-off at inception of the contributed technology by Elan and Elan Pharma to Incara Development and \$173,000 for net losses.

Purchased in-process research and development expenses for the six months ended March 31, 2000 resulted from the acquisition of the minority interests of Aeolus and Incara Cell Technologies in March 2000. The acquisition

Edgar Filing: INCARA PHARMACEUTICALS CORP - Form 10-Q/A

was accounted for using the purchase method of accounting. The total purchase price of \$6,664,000 was allocated to purchase of in-process research and development and immediately charged to operations because the in-process research purchased was in preclinical stages and feasibility had not been established at the date of the acquisition. At that time, we deemed the in-process research to have no alternative future use.

General and administrative, or G&A, expenses increased \$73,000, or 11%, to \$763,000 for the three months ended March 31, 2001 from \$690,000 for the three months ended March 31, 2000. G&A expenses increased \$194,000, or 15%, to \$1,446,000 for the six months ended March 31, 2001 from \$1,252,000 for the six months ended March 31, 2000.

Incara accreted \$214,000 of dividends on its Series C Stock during the three and six months ended March 31, 2001. From the date of issue until the earlier of December 31, 2006 or the date the Series C Stock is exchanged or converted, Incara will accrete the Series C Stock from its recorded value up to its face value plus the 7% dividend, compounded annually.

Liquidity and Capital Resources

At March 31, 2001, we had cash and cash equivalents and marketable securities of \$4,954,000, a decrease of \$1,601,000 from September 30, 2000. Cash decreased primarily due to the operating expenses of \$4,821,000 for the six months, offset by \$4,000,000 received from

12

the net effect of investment transactions with Elan. We believe we have adequate financial resources to fund our current operations at least through fiscal 2001.

Our cash requirements for subsequent periods will depend on numerous factors, particularly the progress of our R&D programs. Significant additional funds will be required for the development activities in our liver cell and antioxidant programs, the cost of new equipment and leasehold improvements for a new leased laboratory facility for our liver cell program currently under construction, and to continue Incara's portion of Incara Development's clinical program evaluating the use of OP2000, a low-weight molecular heparin, in the treatment of inflammatory bowel disease. Subject to the mutual consent of Elan and Incara, Elan will lend Incara up to \$4,806,000 to help fund Incara's 80.1% pro rata interest in the operating costs of Incara Development.

To execute our business plan, we intend to seek the necessary additional capital through one or more potential sources, including the sale of common or preferred stock in private or public equity offerings and new collaborations related to one or more of our product development programs. We have filed a shelf registration with the SEC for the sale of up to \$10,000,000 of our securities and we have established an equity financing line with Torneaux Fund Ltd. for the sale of common stock. However, due to market conditions and other limitations on these offerings, we might not be able to sell securities under these arrangements, or raise other funds on terms acceptable or favorable to us. At times it is difficult for biotechnology companies to raise funds in the equity markets. Any additional equity financing, if available, would likely result in substantial dilution to Incara's stockholders. If we are successful in obtaining collaborations for any of our programs, we might have to relinquish rights to technologies, product candidates or markets that we might otherwise develop ourselves. If we are unable to enter into new collaborations or raise additional capital to support our current level of operations, we might be required to scale back, delay or discontinue one or more of our programs, or obtain funds on terms that are not favorable to us, which could have a material

Edgar Filing: INCARA PHARMACEUTICALS CORP - Form 10-Q/A

adverse affect on our business. Reduction or discontinuation of programs could result in additional charges, which would be reflected in the period of the reduction or discontinuation.

13

Part II. OTHER INFORMATION

Item 2. Changes in Securities and Use of Proceeds

On January 22, 2001, Incara closed on a transaction in which Elan International Services, Ltd. purchased 825,000 shares of Incara's common stock, 28,457 shares of Incara Series B non-voting convertible preferred stock and a five-year warrant to purchase 22,191 shares of Series B Stock at an exercise price of \$72.12 per share for an aggregate purchase price of \$4,000,000. Each share of Series B Stock is convertible into ten shares of common stock. Elan International also purchased 12,015 shares of Incara Series C convertible exchangeable non-voting preferred stock. This Series C Stock has a face value of \$12,015,000 and bears a mandatory stock dividend of 7%, compounded annually. The Series C Stock is exchangeable at the option of Elan International at any time for all of the preferred stock of Incara Development, Ltd. held by Incara which, if exchanged, would give Elan International ownership of 50% of the initial amount of combined common and preferred stock of Incara Development. After December 20, 2002, the Series C Stock is convertible by Elan International into shares of Incara's Series B Stock at the rate of \$64.90 per share. If the Series C Stock is outstanding as of December 21, 2006, Incara will exchange the Series C Stock and accrued dividends, at its option, for either cash or shares of stock and warrants of Incara having a then fair market value of the amount due. This transaction was exempt from registration under Section 4(2) of the Securities Act of 1933, or Regulation S.

Item 4. Submission of Matters to a Vote of Security Holders

The Annual Meeting of Stockholders of Incara was held on March 27, 2001. The following is a brief description of each matter voted upon at the meeting and the number of affirmative votes and the number of negative votes cast with respect to each matter.

- (a) The stockholders elected the following persons as directors of Incara: Clayton I. Duncan; David B. Sharrock; Edgar H. Schollmaier; and Stephen M. Prescott. The votes for and against (withheld) each nominee were as follows:

Nominee	Votes For	Votes Withheld	Votes Abstained
-----	---	-----	-----
Clayton I. Duncan	7,105,635	232,563	0
David B. Sharrock	7,105,688	232,510	0
Edgar H. Schollmaier	7,105,688	232,510	0
Stephen M. Prescott	7,105,688	232,510	0

- (b) The stockholders approved an amendment to the Incara Pharmaceuticals Corporation 1994 Stock Option Plan to increase the number of shares of common stock reserved for issuance thereunder from 2,500,000 shares to 3,500,000 shares, with 4,602,653 shares voting for approval, 305,312 shares voting against, 17,359 shares abstained and 2,412,874 shares were broker non-votes.

14

Edgar Filing: INCARA PHARMACEUTICALS CORP - Form 10-Q/A

- (c) The stockholders approved the sale of up to \$10,000,000 of Incara's securities pursuant to a shelf registration filed with the SEC, with 4,221,190 shares voting for approval, 238,100 shares voting against, 466,034 shares abstained and 2,412,874 shares were broker non-votes.
- (d) The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent auditors of Incara for the fiscal year ending September 30, 2001, with 7,302,513 shares voting for, 24,853 shares voting against, 10,832 shares abstained and 10,832 shares were broker non-votes.

Item 6. Exhibits and Reports on Form 8-K.

(a) Exhibits

- 10.64* Agreement and Amendment, effective as of January 22, 2001, by and among Incara Pharmaceuticals Corporation, Elan International Services, Ltd. and Elan Pharma International Limited.
- 10.65* Second Agreement and Amendment, effective as of January 22, 2001, by and among Incara Pharmaceuticals Corporation, Elan International Services, Ltd. and Elan Pharma International Limited.

* Previously filed as the identically numbered exhibit to the Registrant's quarterly report on Form 10-Q filed on May 14, 2001

(b) The following reports on Form 8-K were filed by the Company during the three months ended March 31, 2001.

Date Filed	Event
-----	-----
January 29, 2001	Transaction with Elan Corporation, plc and subsidiaries
March 27, 2001	Pro forma balance sheet reflecting the transaction with Elan Corporation, plc and subsidiaries

15

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report on Form 10-Q/A Amendment No. 1 to be signed on its behalf by the undersigned thereunto duly authorized.

INCARA PHARMACEUTICALS CORPORATION

Date: July 30, 2001

By: /s/ Richard W. Reichow

Richard W. Reichow, Executive Vice President,
Chief Financial Officer and Treasurer
(Principal Financial and Accounting Officer)

16